Cabral-Miranda, G.; Heath, M.D.; Gomes, A.C.; Mohsen, M.O.; Montoya-Diaz, E.; Salman, A.M.; Atcheson, E.; Skinner, M.A.; Kramer, M.F.; Reyes-Sandoval, A.;
et al. Microcrystalline Tyrosine (MCT®): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria. Vaccines 2017, 5, 32.
https://doi.org/10.3390/vaccines5040032
AMA Style
Cabral-Miranda G, Heath MD, Gomes AC, Mohsen MO, Montoya-Diaz E, Salman AM, Atcheson E, Skinner MA, Kramer MF, Reyes-Sandoval A,
et al. Microcrystalline Tyrosine (MCT®): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria. Vaccines. 2017; 5(4):32.
https://doi.org/10.3390/vaccines5040032
Chicago/Turabian Style
Cabral-Miranda, Gustavo, Matthew D. Heath, Ariane C. Gomes, Mona O. Mohsen, Eduardo Montoya-Diaz, Ahmed M. Salman, Erwan Atcheson, Murray A. Skinner, Matthias F. Kramer, Arturo Reyes-Sandoval,
and et al. 2017. "Microcrystalline Tyrosine (MCT®): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria" Vaccines 5, no. 4: 32.
https://doi.org/10.3390/vaccines5040032
APA Style
Cabral-Miranda, G., Heath, M. D., Gomes, A. C., Mohsen, M. O., Montoya-Diaz, E., Salman, A. M., Atcheson, E., Skinner, M. A., Kramer, M. F., Reyes-Sandoval, A., & Bachmann, M. F.
(2017). Microcrystalline Tyrosine (MCT®): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria. Vaccines, 5(4), 32.
https://doi.org/10.3390/vaccines5040032